|
gptkbp:instanceOf
|
gptkb:drug
antiviral drug
|
|
gptkbp:approvedBy
|
gptkb:World_Health_Organization
1992
|
|
gptkbp:ATCCode
|
gptkb:P01BE03
|
|
gptkbp:CASNumber
|
88495-63-0
|
|
gptkbp:chemicalFormula
|
C19H28O8
|
|
gptkbp:combines
|
gptkb:amodiaquine
gptkb:clindamycin
gptkb:mefloquine
gptkb:sulfadoxine-pyrimethamine
doxycycline
|
|
gptkbp:contraindication
|
hypersensitivity to artemisinins
|
|
gptkbp:derivedFrom
|
gptkb:artemisinin
|
|
gptkbp:developedBy
|
gptkb:China
|
|
gptkbp:eliminationHalfLife
|
0.5 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
artesunate
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits parasite growth
|
|
gptkbp:metabolism
|
gptkb:dihydroartemisinin
|
|
gptkbp:molecularWeight
|
384.42 g/mol
|
|
gptkbp:origin
|
semi-synthetic derivative of artemisinin
|
|
gptkbp:pregnancyCategory
|
C
|
|
gptkbp:PubChem_CID
|
6917864
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular
intravenous
rectal
|
|
gptkbp:sideEffect
|
gptkb:anemia
nausea
vomiting
allergic reactions
|
|
gptkbp:treatment
|
gptkb:Plasmodium_falciparum_malaria
severe malaria
uncomplicated malaria
|
|
gptkbp:UNII
|
KQ1C2X9M2G
|
|
gptkbp:usedFor
|
treatment of malaria
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
included
|
|
gptkbp:bfsParent
|
gptkb:Project_523
|
|
gptkbp:bfsLayer
|
5
|